Esperion Therapeutics Inc (ESPR) concluded trading on Wednesday at a closing price of $1.00, with 5.24 million shares of worth about $5.24 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.41% during that period and on April 30, 2025 the price saw a gain of about 4.12%. Currently the company’s common shares owned by public are about 195.85M shares, out of which, 194.67M shares are available for trading.
Stock saw a price change of 5.29% in past 5 days and over the past one month there was a price change of -30.60%. Year-to-date (YTD), ESPR shares are showing a performance of -54.57% which decreased to -47.40% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.82 but also hit the highest price of $3.94 during that period. The average intraday trading volume for Esperion Therapeutics Inc shares is 4.51 million. The stock is currently trading -2.53% below its 20-day simple moving average (SMA20), while that difference is down -28.28% for SMA50 and it goes to -48.66% lower than SMA200.
Esperion Therapeutics Inc (NASDAQ: ESPR) currently have 195.85M outstanding shares and institutions hold larger chunk of about 58.69% of that.
The stock has a current market capitalization of $198.03M and its 3Y-monthly beta is at 0.75. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 0.99. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ESPR, volatility over the week remained 9.74% while standing at 10.08% over the month.
Stock’s fiscal year EPS is expected to rise by 84.04% while it is estimated to decrease by -363.95% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on December 18, 2024 offering a Neutral rating for the stock and assigned a target price of $4 to it. Coverage by Cantor Fitzgerald stated Esperion Therapeutics Inc (ESPR) stock as an Overweight in their note to investors on December 17, 2024, suggesting a price target of $8 for the stock. Stock get a Neutral rating from JP Morgan on November 20, 2023.
